2017 Scientific Committee

Dr. John-Paul Carpenter

Consultant Cardiologist, Poole Hospital NHS Foundation Trust, Burley, Hamshire, UK

Dr. Susan Dent, MD, FRCPC

President, Canadian Cardiac Oncology Network; Medical Oncologist, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada

founder

Dr. Dent is a Medical Oncologist at The Ottawa Hospital Cancer Centre and Associate Professor in the Department of Medicine at the University of Ottawa.  She obtained her MD at McMaster University and completed her postgraduate training in Internal Medicine at the University of Ottawa. She continued her training in Medical Oncology in Ottawa, followed by a fellowship year in Clinical Research with the National Cancer Institute of Canada Clinical Trials Group.

Read More...

She is the research lead for the breast disease site group at the Ottawa Hospital Cancer Centre, and a member of the IND working group for the Breast Cancer Disease Site Committee of the National Cancer Institute for Canada Clinical Trials Group. Her areas of research interest include breast cancer, and treatment related toxicities with a particular interest in cardiotoxicity. She is the founder of the Ottawa Cardiac Oncology Program as well as the Canadian Cardiac Oncology Network, organizations dedicated to improving our understanding of how cancer treatments impact cardiovascular health with the ultimate goal of preventing cardiotoxicity.

Dr. Martin Denvir

Consultant Cardiologist, University of Edinburgh, Edinburgh, UK

Prof. Helena Earl

Professor of Clinical Cancer Medicine; Honorary Consultant Medical Oncologist, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

founder

Professor Helena Earl completed a PhD in Breast Cancer in 1985 and specialist training in Medical Oncology with General Internal Medicine at UCLH in 1991. In 1992 she joined the University of Birmingham and was Director of the Cancer Research UK Clinical Trials Unit, moving to the University of Cambridge, Department of Oncology in 1996. She is active in clinical and translational research and leads NCRN clinical trials in breast cancer (NEAT, tAnGo, Neo-tAnGo, ARTemis, PERSEPHONE, and PARTNER). 

Read More...

Professor Earl holds grant funding from Cancer Research UK, the NIHR HTA, and pharmaceutical partners. She is a PI in the Cancer Research UK Cambridge Cancer Centre, NIHR BRC, ECMC, CCTC, and Cambridge Breast Cancer Research Unit. She is an active member of the Cambridge Trials Methodology Group developing linked Bayesian Adaptive Randomised (BAR) designs, with biomarkers and new treatments, integrating early biomarkers of response into these designs. Professor Earl has published her research in cardio-oncology from the PERSEPHONE Trial of adjuvant trastuzumab duration.

Dr. Mark Harbinson

Consultant Cardiologist, Queen's University Belfast, Belfast, Northern Ireland, UK

Dr. Daniel Lenihan, MD

President, International CardiOncology Society - North America; Professor of Medicine; Director, Clinical Research Program, Vanderbilt Heart and Vascular Institute, Nashville, TN, USA

founder

Dr. Lenihan, has been active in clinical research in cardiology, and specifically in heart failure, for nearly 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer.

Read More...

His current projects include early phase clinical trials in heart failure, including the recently presented Phase 1 trial of GGF2 in cooperation with Acorda, Inc. As the Director of Clinical Research in the Division of Cardiovascular Medicine, Dr Lenihan is managing over 100 clinical trials in conjunction with all of VHVI faculty and continues to enhance and foster collaboration among a host of colleagues both internally and throughout the world. He is the current president (US/Canada) of the International CardiOncology Society, a professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Dr. Alexander Lyon, MA, BM, BCh, PhD, FRCP

GCOS 2017 Co-Chair; British Heart Failure Foundation Senior Lecturer in Cardiology, Imperial College London; Consultant Cardiologist & Clinical Lead for Cardio-Oncology Service, Royal Brompton Hospital, London, United Kingdom. President of the British Cardio-Oncology Society.

founder

Dr. Alexander Lyon is a British Heart Foundation Senior Lecturer in Cardiology at Imperial College London and a Consultant Cardiologist at the Royal Brompton Hospital. He studied medicine at Oxford University where he gained a first class degree, and studied for his PhD thesis in myocardial gene therapy at Imperial College London.

Read More...

He continued his gene therapy research during a postdoctoral research year in the laboratory of Roger Hajjar at Mount Sinai Hospital in New York. His clinical interests are in the field of heart failure, cardio-oncology and Takotsubo syndrome, and he is the theme leader for heart failure research in the NIHR-funded Biomedical Research Unit at the Royal Brompton Hospital. He is the clinical lead for the new Cardio-Oncology service at the Royal Brompton hospital, specialising in surveillance and cardioprotection from modern cancer drugs, risk stratification and treatment of all cardiac complications of cancer treatment. He is the president of the British Cardio-Oncology Society and a member of the European Society of Cardiology Taskforce on Cardio-Oncology. He is the clinical advisor to the british cancer patient charity Macmillan Cancer and helped to write the first patient information leaflet – Heart health for Cancer Patients. He is the UK national lead investigator for two gene therapy trials for chronic heart failure (CUPID2 and SERCA-LVAD), and is the heart failure lead for the RDN-HFpEF study assessing the role of renal sympathetic denervation for individuals with heart failure with preserved ejection fraction. He is leading both a laboratory research programme understanding the influence of stress and high catecholamine levels upon myocardial function, and he is coordinating both a national and European strategy to advance knowledge and improve care for individuals with Takotsubo syndrome. He runs a specialist clinic for patients with Takotsubo syndrome focussing on risk prediction and management of refractory symptoms.

Dr. Charlotte Manisty

Senior Lecturer, University College London; Consultant Cardiologist, The Heart Hospital and Barts Health NHS Foundation Trust, London, United Kingdom

Piers McCleery

Royal Brompton & Harefield NHS Foundation Trust Board, London, United Kingdom

Dr. Theresa McDonagh

Professor of Heart Failure and Consultant Cardiologist, King's College Hospital, London, United Kingdom

Dr. John McGowan

Clinical Research Associate, University College London Hatter Cardiovascular Institute; Hon Cardiology Research Fellow, UCH, London, United Kingdom

Dr. Chris J. Plummer, MD

Consultant Cardiologist, Freeman Hospital, Newcastle, England

founder

Dr Plummer is a consultant cardiologist at the Freeman Hospital in Newcastle upon Tyne. His clinical work focuses on cardiac implantable electronic device therapies but he also has a major clinical and research interest in cardiovascular effects of cancer treatments. He has co-written cardio-oncology guidance in 3 areas, given advice on more than 50 clinical trials and co-founded the British Cardio-Oncology Society in 2014 where he is Secretary and wrote/published BC-OS.org.

Read More...

He trained in Bristol where he gained a PhD, St John's College Oxford where he completed his medical degree and in Newcastle where he undertook cardiology training. He is also involved in medical education from interviewing medical students to being the cardiology training programme director in the North East and serving on the exam board for the European General Cardiology Examination.

Dr. Sanjay Prasad

Consultant Cardiologist, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom

Prof. John Radford

Professor of Medical Oncology and Director of Research, The Christie Hospital; Molecular & Clinical Cancer Sciences University of Manchester, Manchester, United Kingdom

founder

John Radford is Professor of Medical Oncology and Director of Research at The Christie Hospital, Manchester. Research interests are focused on developing and testing new ways of treating lymphoma and monitoring the effectiveness of these treatments using novel biomarkers, studying late effects of chemotherapy on fertility, heart function and the risk of second cancers and investigating how best to prevent or minimise the impact of these in people cured of lymphoma. 

Read More...

John is chair of the UK National Cancer Research Institute (NCRI) Lymphoma Clinical Studies Group, a member NCRI Hodgkin Lymphoma sub-group and chief investigator for many national and international trials.

Dr. Simon Ray

Consultant Cardiologist, The University Hospital of Manchester, Manchester, United Kingdom

Dr. Stuart D Rosen, MA, MD, FRCP, FESC, FACC, FHFA

Consultant Cardiologist, Royal Brompton and London Northwest Healthcare Hospitals; Reader in Cardiology, National Heart and Lung Institute, Imperial College London; United Kingdom. Treasurer of the British Cardio-Oncology Society.

founder

Dr Stuart Rosen is Consultant Cardiologist, Royal Brompton and London Northwest Healthcare Hospitals and Reader in Cardiology, National Heart and Lung Institute, Imperial College London; United Kingdom. He received his medical undergraduate education at Pembroke College, Cambridge and at Charing Cross and Westminster Medical School. His specialist cardiology training was at Charing Cross, Hammersmith and St Mary’s Hospitals.

Read More...

In clinical practice, Dr Rosen is a general adult cardiologist and has specialist expertise in heart failure, syncope and hypertension. His technical skills include transoesophageal echocardiography, stress echo, tilt testing and autonomic assessment, as well as ultrafiltration for decompensated heart failure. Dr Rosen had a pivotal role in setting up the UK’s first cardio-oncology unit, at the Royal Brompton Hospital, to provide bespoke care for patients at risk of cardiotoxicity or who have developed cardiac problems as a consequence of their anti-cancer treatment. He is Founding Treasurer of the British Cardio-Oncology Society. Dr Rosen has a programme of translational research focused on: Role of cardiac autonomic dysfunction in pathophysiology of cardiac disease; Origins of cardiac pain [member of an international task force on complex cardiac pain syndromes]; Mechanisms of heart injury in cancer patients. He is also cardiologist to the MRC’s Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial, a multi centre study of cardiovascular outcomes in prostate cancer patients treated with transcutaneous oestrogen patches compared with LHRH analogues. Dr Rosen has a busy managerial role as Clinical Director of Medicine at LNW Hospitals. He also has extensive teaching commitments, in medicine, cardiology, ethics and law for medical undergraduates and supervises postgraduates, MD and PhD students. Dr Rosen is author of more than 70 peer reviewed papers, plus review articles, editorials, abstracts, nine book chapters two books.

Prof. Roderick Skinner

Consultant in Paediatric and Adolescent Oncology/Bone Marrow Transplantation, Great North Children's Hospital, Royal Victoria Infirmary; Honorary Professor of Childhood Cancer, Northern Institute of Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom

founder

Professor Rod Skinner has been a Consultant in Paediatric and Adolescent Oncology / BMT at the Great North Children’s Hospital, Royal Victoria Infirmary, Newcastle upon Tyne since January 1996, and is an Honorary Professor of Childhood Cancer, Northern Institute of Cancer Research, Newcastle University. He qualified in Birmingham in 1983, trained initially in general paediatrics and then in paediatric haematology/oncology and BMT in Newcastle, with further BMT experience in the Pediatric BMT Program, Minneapolis, USA. 

Read More...

He was awarded a PhD by Newcastle University in 1995 for his research thesis into chemotherapy-induced nephrotoxicity in children with cancer. He is the clinical lead in Newcastle for paediatric haematology allogeneic haemopoietic stem cell transplantation, long-term follow-up (LTFU), and bone marrow failure, and has a busy practice in paediatric / adolescent leukaemia. His research interests include late adverse effects of childhood cancer treatment, especially nephrotoxicity, and LTFU of childhood cancer survivors. He has played a leading role in the development of evidence-based, internationally-harmonised LTFU surveillance guidelines. He is a member of the UK Children’s Cancer and Leukaemia Group, with leading roles in the Late Effects Group (current chair), Supportive Care Group (chair 2003-08) and BMT Group (chair 2008-2012). He was a National Clinical Advisor in the NHS National Cancer Survivorship Initiative (2008-2012). He was one of the three instigators and founding members in 2008 of PanCare (Pan-European Network for Care of Survivors after Childhood and Adolescent Cancer), and remains on its Executive Board.

Dr. Susannah Stanway, MBChB, MRCP, MD, MSc

GCOS 2017 Co-Chair; Consultant in Medical Oncology, The Royal Marsden NHS Foundation Trust, London, United Kingdom

founder

Dr Susannah Stanway is a Consultant in Medical Oncology at The Royal Marsden NHS Foundation Trust. Having qualified from Bristol University in 1998, she obtained an MD thesis for her work on Steroid Sulphatase Inhibition in postmenopausal patients with Breast Cancer from Imperial College in 2009; her oncology training was undertaken at UCLH and The Royal Marsden NHS Foundation Trust. 

Read More...

She has been working at consultant level since 2012, both in the Acute Oncology Service at Croydon University Hospital and in the Royal Marsden NHS Foundation Trust’s Breast Unit. Along with actively recruiting patients to the large portfolio of research studies in the Breast Unit, her research interest is predominantly focused on Cancer Survivorship. This includes the area of cardio-oncology, in collaboration with amongst others, the Cardio-Oncology Group at the Royal Brompton Hospital and the London School of Hygiene and Tropical Medicine; treatment-induced Hot Flushes, where she sits on the NCRI Symptom Management Working Group; sexual and psychological consequences of cancer and has completed an MSc thesis on Risk Stratification to Guide Follow up after Childhood Malignancy. She co-chairs the Royal Marsden NHS Foundation Trust’s Living With and Beyond Cancer Committee; sits on the Royal Marsden Partners Survivorship pathway and has set up a pan-London multi-disciplinary survivorship research group; she leads the Living with and Beyond Cancer Module on the Institute of Cancer Research (ICR) MSc course; and has been actively involved with the Royal Marsden NHS Foundation Trust’s Young Women’s Breast Cancer Program since its inception; She has a personal interest in cancer control in low-middle income countries and she sits on the editorial board of ASCO’s Journal of Global Oncology, leads a sub-module on Cancer in Low-Middle Income Countries on the ICR MSc course and actively contributes to oncology education in East Africa with the Royal College of Physicians. She is immediate past president of the Oncology Section at the Royal Society of Medicine.

Dr. Jay Wright

Lead Clinician for Heart Failure and Cardiac Devices, Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, United Kingdom